Infant Bacterial Therapeutics AB (publ) (IBT), Interim Management Statement, July 1 – September 30, 2022
10 nov. 2022 02h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO Our IBP-9414 clinical phase III development project is progressing well, and as previously mentioned, we are pursuing several initiatives to accelerate study execution. It is...
Jøtul Group - Interim financial report for the half-year ended 30. June 2022
26 août 2022 04h30 HE
|
Jøtul AS
In the first half of 2022, the Jotul Group reached a consolidated profit of MNOK 15.2 (H1 2021: loss of MNOK 54.1). The operating profit totaled MNOK 65.4 in H1 2022 (H1 2021: loss of MNOK 1.2). The...
Pieridae to Hold Conference Call and Webcast on Q2 2022 Results
12 juil. 2022 08h00 HE
|
Pieridae Energy Limited
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATESCALGARY, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Pieridae Energy Limited (“Pieridae” or the “Company”)...
Inventiva publie ses informations financières du 1er trimestre 2022 et fait un point sur ses développements cliniques
16 mai 2022 16h00 HE
|
INVENTIVA
Position de trésorerie2 à €80.5 M€ au 31 mars 2022Le Groupe n’a pas généré de chiffre d’affaires au T1 2022Obtention d’un crédit « in fine » d’un montant de 50 millions d'euros de la part de la Banque...
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
16 mai 2022 16h00 HE
|
INVENTIVA
Cash position2 at €80.5m as of March 31, 2022The Group did not generate any revenue in Q1 2022Signature of a €50 million bullet credit facility agreement with the European Investment BankUpdate on...
Infant Bacterial Therapeutics AB (publ), (IBT) delårsrapport 1 januari – 31 mars 2022
04 mai 2022 12h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar IBT:s vision är att bli ett internationellt ledande företag genom utveckling av läkemedel inom områdena för tidigt födda barn, gastrointestinala sjukdomar och probiotika. Vi har nu...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2022
04 mai 2022 12h00 HE
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT's vision is to become an internationally leading company in the development of pharmaceuticals in the areas of premature infants, gastrointestinal diseases and probiotics. ...
CAST revenue stable in Q1 as CAST confirms transition to annual subscriptions
03 mai 2022 17h39 HE
|
CAST Software Inc.
Revenue in M€20222021Variation% TCC*T18,89,0-0,16-1,7 % * At current exchange rate NEW YORK and PARIS, May 03, 2022 (GLOBE NEWSWIRE) -- First quarter revenue amounted to €8.8 million, nearly same...
Jøtul Group - Annual report and Independent auditor’s report for the year ended 31 December 2021
29 avr. 2022 17h45 HE
|
Jøtul AS
The Jøtul Group (representing Jøtul AS together with its subsidiaries) is one of the three largest suppliers of fireplaces in Europe and a significant player in North America. The company, with a...
Infant Bacterial Therapeutics publishes Annual Report for 2021
31 mars 2022 02h00 HE
|
Infant Bacterial Therapeutics AB
Press release March 31, 2022 Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section...